drugset / Trial / NCT00835354
Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study is to compare the relative bioavailability of cefprozil for oral suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension 250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under non-fasting conditions.
Timeline
- Start
- 2004-05
- Primary completion
- 2004-05
- Completion
- 2004-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CEFPROZIL ANHYDROUS, (E)- | Small molecule | 250 mg | Oral |
Indications
No indication recorded.